

CLAIMS

1. Use of tipifarnib in the manufacture of a medicament for the treatment of cetuximab-refractory squamous cell carcinoma of the head and neck (SCCHN) in a subject, wherein the SCCHN has an HRAS mutation.

2. The use of claim 1, wherein said HRAS mutation comprises an amino acid substitution at a codon selected from a group consisting of G12, G13, Q61, Q22, K117, A146, and any combination thereof.

3. The use of claim 1 or 2, wherein said SCCHN does not have K-Ras mutation or N-Ras mutation.

4. The use of claim 3, wherein said SCCHN has wild type K-Ras and wild type N-Ras.

5. The use of claim 1 to 4, wherein said SCCHN is HPV negative.

6. The use of claim 1 to 5, wherein said SCCHN is recurrent or metastatic.

7. The use of claim 1 to 6, wherein said SCCHN is relapsed SCCHN.

8. The use of claim 1 to 7, wherein the SCCHN is SCCHN of the trachea.

9. The use of claim 1 to 7, wherein the SCCHN is SCCHN of the maxilla.

10. The use of claim 1 to 7, wherein the SCCHN is SCCHN of the oral cavity.

11. Use of tipifarnib in the manufacture of a medicament for the treatment of cetuximab-refractory lung squamous cell carcinoma (lung SCC) in a subject, wherein the lung SCC has an HRAS mutation.

12. The use of claim 11, wherein said HRAS mutation comprises an amino acid substitution at a codon selected from a group consisting of G12, G13, Q61, Q22, K117, A146, and any combination thereof.

13. The use of claim 11 or 12, wherein said lung SCC does not have K-Ras mutation or N-Ras mutation.

14. The use of claim 13, wherein said lung SCC has wild type K-Ras and wild type N-Ras.

15. The use of any one of claims 11 to 14, wherein said lung SCC is HPV negative.

16. The use of any one of claims 11 to 15, wherein said lung SCC is at an advanced stage or metastatic.

17. The use of any one of claims 11 to 16, wherein said lung SCC is relapsed lung SCC.